[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Universität Münster\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":356},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,43,72,100,129,156,185,214,240,261,284,307,332],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":27,"conditions":28,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100484641","phase-1-radiodynamic-therapy-rdt-with-gliolan-in-patients-with-first-recurrence-of-brain-tumor-100484641",false,"NCT05590689","Radiodynamic Therapy (RDT) With Gliolan in Patients With First Recurrence of Brain Tumor","Phase I\u002FII Dose Escalation Trial of Radiodynamic Therapy (RDT) With 5-Aminolevulinic Acid in Patients With First Recurrence of Glioblastoma","ALA-RDTinGBM","Inclusion Criteria:\n\n* Written patient consent after comprehensive information\n* Age \\>\u002F= 18 years\n* Recurrence of supratentorial glioblastoma after initial resection and adjuvant therapy (e.g. radio-chemotherapy, targeted therapies, antiangiogenic therapies as determined by the tumor board) (with planned second resection cohort 0 and 1), second or third recurrences permitted\n* Clinically indicated further radiotherapy as per decision of the tumor board as part of therapy for recurrence\n* Histological verification of recurrent glioblastoma independent of methylated MGMT promotor status when alkylating chemotherapy failed at this time.\n* Karnofsky Performance Score ≥ 60\n* For female and male patients and their female partners of childbearing\u002Freproductive potential(\\*): Willingness to apply highly effective contraception (Pearl index \\\u003C1) during the entire study (and for at least 6 months after the first application of 5-ALA). Such methods include:\n\n  1. combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation: I. oral II. intravaginal III. transdermal\n  2. progestogen only hormonal contraception associated with inhibition of ovulation: I. oral II. injectable III. implantable\n  3. intrauterine device (IUD)\n  4. intrauterine hormone-releasing system (IUS)\n  5. bilateral tubal occlusion\n  6. vasectomised partner\n  7. male patients have to use a condom\n  8. sexual abstinence\n* Pre-menopausal(\\*) female patients with childbearing potential: a negative pregnancy test must be obtained max. 72h prior to treatment start\n* Adequate liver function: bilirubin \\\u003C 1.5 times above upper limit of normal range (ULN), alanine transaminase (ALT\u002FSGPT) and aspartate transaminase (AST\u002FSGOT) \\\u003C 3 times ULN. In the case of documented or suspected Gilbert's disease bilirubin \\\u003C 3 times ULN.\n* Adequate renal function: creatinine \\\u003C 3 times above ULN; eGFR \\>\u002F= 60 ml\u002Fmin, Blood clotting: INR\u002FQuick\u002FPT and PTT within acceptable limits according to the investigator.\n\n(\\*) Definition: A man is considered of reproductive potential after puberty unless permanently sterile by bilateral orchidectomy. A woman is considered of childbearing potential (WOCBP), i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. A post-menopausal state is defined as no menses for 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a post-menopausal state in women not using hormonal contraception or hormonal replacement therapy. However in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient.\n\nExclusion Criteria:\n\n* Patient unable to undergo imaging by MRI, PET or contrast-enhanced CT for whatever reason (e.g. pace-maker)\n* Pregnant and breastfeeding women\n* Past medical history of diseases with poor prognosis, e.g., severe coronary heart disease, heart failure (NYHA III\u002FIV), severe and poorly controlled diabetes, immune deficiency, residual deficits after stroke, severe mental retardation or other serious concomitant systemic disorders incompatible with the study (at the discretion of the investigator)\n* Any active infection (at the discretion of the investigator)\n* Hypersensitivity against porphyrins\n* Known diagnosis of porphyria\n* Participation in another clinical trial with therapeutic intervention or use of any other therapeutic interventional agent other than the standard therapy since diagnosis of glioblastoma\n* Known intolerance to study medication\n* Pre-treatment with other potentially phototoxic or photosensitizing substances (e.g. tetracyclines, sulfonamides, fluoroquinolones, hypericin extracts, products containing St. John's wort ) during the 2 weeks preceding RDT","ALL","18 Years","75 Years",{"count":21,"type":22},34,"ESTIMATED","INTERVENTIONAL",[25,26],"PHASE1","PHASE2","The investigational drug 5-ALA (known under the trade name Gliolan®) is an approved drug for the surgical removal of malignant glioma (WHO grade III and IV). In this trial, the drug is being tested outside of its actual approval as a radiosensitizer in combination with conventional radiotherapy for first-time recurrence (relapse) of malignant glioma. In this clinical trial, the investigational drug 5-ALA is being used for the first time in a multiple dose escalation regimen in combination with radiotherapy following surgical removal of a recurrent malignant glioma in humans. The investigational drug, 5-ALA, has been used as a single dose to date as a standard of care for visualization of malignant tissue in the surgical removal of gliomas.\n\nThe planned clinical trial will first and foremost investigate how well repeated administration of the investigational drug 5-ALA is tolerated in combination with radiotherapy. At the same time, the design of the trial serves to optimize this novel therapeutic procedure with regard to the frequency of administration of the investigational drug 5-ALA in combination with radiotherapy for future clinical trials.\n\nAs a secondary objective, the efficacy of additional 5-ALA administration will also be investigated.",[29],"Glioblastoma","RECRUITING","2026-06-19",{"date":33,"type":34},"2026-06-23","ACTUAL",{"date":36,"type":34},"2022-11-09",{"date":38,"type":22},"2028-01",{"name":40,"class":41},"Universität Münster","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":23,"phases":53,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":42},"100641871","the-effect-of-standard-vs-shorter-filter-lifespan-during-continuous-renal-replacement-therapy-100641871","NCT07630220","The Effect of Standard vs. Shorter Filter Lifespan During Continuous Renal Replacement Therapy","The Effect of Standard vs. Shorter Filter Lifespan During Continuous Renal Replacement Therapy in Critically Ill Patients With Acute Kidney Injury - a Feasibility Randomized Controlled Trial","SPECIAL","Inclusion Criteria:\n\n1. Adult ≥ 18 years\n2. Critically ill patients with severe AKI consistent with KDIGO stage 3 and an absolute indication for CRRT\n3. Written consent form from the patient or legal representative or authorized representative or emergency inclusion\n\nExclusion Criteria:\n\n1. End-stage kidney disease or chronic dialysis dependence\n2. Chronic kidney disease with eGFR\\\u003C20ml\u002Fmin\u002F1.73 m²\n3. Prior kidney transplant\n4. Prior renal replacement therapy during the index admission before randomization\n5. Glomerulonephritis, interstitial nephritis, vasculitis\n6. Patients on immunosuppression (above the cushing threshold)\n7. Patients with chronic inflammatory diseases (e.g. arthritis, HIV with a CD4 count of \\\u003C 0.05 x 10E\u002Fl)\n8. Do-not resuscitate order\n9. Persons with any kind of dependency on the investigator or employed by the sponsor\n10. Patients participating in an interventional study involving measures to influence the immune system",{"count":52,"type":22},100,[54],"NA","This study aims to investigate shorter vs. standard filter lifespans in critically ill patients receiving continuous renal replacement therapy (CRRT) for acute kidney injury (AKI). The aim of this trial is to reliably implement,scheduled filter changes and to investigate whether shorter filter lifetime is associated with a lower incidence in rate of new infections.",[57],"Acute Kidney Injury",[59,60,61,62],"Continuous Renal Replacement Therapy (CRRT)","Infection","filter change","critical illness","NOT_YET_RECRUITING","2026-06-10",{"date":66,"type":34},"2026-06-15",{"date":68,"type":22},"2026-06",{"date":70,"type":22},"2028-06",{"name":40,"class":41},{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":23,"phases":81,"briefSummary":82,"conditions":83,"keywords":85,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},"100557650","phase-2-multimodal-imaging-with-fapi-petmri-in-breast-carcinoma-in-situ-for-detection-of-occult-invasive-cancer-100557650","NCT06540872","Multimodal Imaging With FAPI-PET\u002FMRI in Breast Carcinoma-In-Situ for Detection of Occult Invasive Cancer","MI-CISDIR","Inclusion Criteria:\n\n* Newly diagnosed DCIS with extent in mammography, MRI or ultrasound suspected to range \\> 4 cm\n* Planned DCIS resection (breast conserving or mastectomy) as per guideline recommendation\n* Written informed consent\n* For women of child bearing potential: confirmed menstrual period (if applicable) and a negative highly sensitive urine or serum pregnancy test\n* Women of childbearing potential (WOCBP) and male patients with partners of childbearing\u002Freproductive potential must agree to use highly effective contraception (Pearl index \\\u003C 1) when sexually active. This applies for the time period between signing of the informed consent form up to the final trial visit.\n\nExclusion Criteria:\n\n* Contraindications for MRI (specific metallic implants, severe claustrophobia, history of anaphylaxis following MRI contrast agent application)\n* GFR \\\u003C 30 mL\u002F(min∙1.73 m²)\n* Current pregnancy or within last 8 weeks before begin of study participation\n* Current nursing or within last 8 weeks before begin of study participation\n* Inability to understand the nature, risks, and benefits of the study\n* History of diagnosis of ipsilateral invasive breast cancer\n* Concurrent diagnosis of contralateral invasive cancer, if not curatively treated by surgery \\> 1 year ago\n* Known hypersensitivity to the active substance or to any of the excipients of the Investigational Medicinal Product",{"count":80,"type":22},30,[26],"DCIS (ductal carcinoma in situ) is a common pre-stage for breast cancer. The goal of this clinical trial is to learn if FAPI-PET\u002FMRI (an imaging technique with a weakly radioactive drug) helps to diagnose hidden invasive breast cancer in participants with DCIS. The main question it aims to answer is:\n\nHow good can FAPI-PET\u002FMRI diagnose hidden invasive breast cancer in DCIS?\n\nResearchers will compare FAPI-PET\u002FMRI results to tissue samples obtained from surgery treatment to see if the FAPI-PET\u002FMRI images show invasive breast cancer certainly.\n\nParticipants will\n\n* receive the radioactive drug and lie in an imaging device for 45 minutes including a break\n* visit the clinic once again for a checkup and test",[84],"Carcinoma, Intraductal, Noninfiltrating",[86,87,88,89,90],"breast cancer","PET\u002FMRI","DCIS","ductal carcinoma in situ","FAPI","2026-06-01",{"date":93,"type":34},"2026-06-03",{"date":95,"type":34},"2026-02-20",{"date":97,"type":22},"2028-03",{"name":40,"class":41},2,{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":106,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":108,"targetDuration":4,"studyType":23,"phases":110,"briefSummary":112,"conditions":113,"keywords":116,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":4},"100628652","phase-4-sodium-bicarbonate-for-critically-ill-patients-with-metabolic-acidosis-and-acute-kidney-injury-100628652","NCT07464431","Sodium Bicarbonate for Critically Ill Patients With Metabolic Acidosis and Acute Kidney Injury","Evaluating the Clinical Effectiveness of Sodium Bicarbonate for Critically Ill Patients With Metabolic Acidosis and Acute Kidney Injury (ESCALATE)","ESCALATE","Inclusion Criteria:\n\n1. Adult ≥ 18 years\n2. Critically ill patients (requiring treatment on an ICU or IMC)\n3. Metabolic acidosis, defined as all of the following:\n\n   1. Arterial pH ≤7.25\n   2. PaCO2 \\\u003C 6.5kPa (\\\u003C49 mmHg)\n   3. Standard bicarbonate ≤20 mmol\u002FL\n   4. Standard Base Excess \\\u003C-2\n4. AKI stage 2 or 3 of the KDIGO classification\n5. Written informed consent of the patient or legal representative or authorized representative or emergency inclusion (according to Article 35 EU-Regulation 536\u002F2014)\n\nExclusion Criteria:\n\n1. Pregnant or breastfeeding patients\n2. Respiratory acidosis (acute or chronic) \\[dynamic, and if corrected, patient may be reconsidered for the trial\\]\n3. Patients on KRT, or KRT immediately indicated and treating clinician(s) unwilling to defer\n4. Deemed unsuitable for KRT\n5. High output stoma\u002Fileostomy\n6. Percutaneous biliary drainage\n7. End stage kidney failure defined as documented eGFR \\\u003C15ml\u002Fmin\u002F1.73m 2 prior to onset of this acute illness or end stage kidney disease (ESKD) on dialysis\n8. Known renal tubular acidosis\n9. Diabetic ketoacidosis\n10. High anion gap acid poisoning (e.g. polyethylene glycol (PEG), aspirin, methanol)\n11. Symptomatic hypocalcaemia (Ionized calcium \\\u003C1.05 mmol\u002FL)\\[dynamic, and if corrected, patient may be reconsidered for the trial\\]\n12. Hypernatremia (plasma sodium \\>150 mmol\u002FL)\\[dynamic, and if corrected, patient may be reconsidered for the trial\\]\n13. Severe hypokalemia (potassium \\\u003C3.0 mmol\u002FL)\\[dynamic, and if corrected, patient may be reconsidered for the trial\\]\n14. Death perceived as imminent\n15. Known hypersensitivity to sodium bicarbonate or EDTA (Disodiumedetate)\n16. Previously randomized into ESCALATE",{"count":109,"type":22},660,[111],"PHASE4","The study investigates whether sodium bicarbonate is able to reduce the occurrence of major adverse kidney events on day 90 (MAKE90) in critically ill patients with metabolic acidosis and acute kidney injury (AKI). While its efficacy in this context has been suggested in a subgroup analysis of the BICAR-ICU trial it has not been confirmed in a double-blinded randomized controlled trial to date.",[57,114,115],"Metabolic Acidosis","Critical Illness",[117,118,119,120],"Acute kidney injury","Metabolic acidosis","Critical illness","Sodium bicarbonate","2026-04-28",{"date":123,"type":34},"2026-05-05",{"date":125,"type":22},"2026-05",{"date":127,"type":22},"2028-12",{"name":40,"class":41},{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":133,"acronym":134,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":23,"phases":138,"briefSummary":139,"conditions":140,"keywords":144,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":42},"100608111","phase-2-combining-loncastuximab-tesirine-and-epcoritamab-in-relapsedrefractory-diffuse-large-b-cell-lymphoma-dlbcl-100608111","NCT07197307","Combining Loncastuximab Tesirine and Epcoritamab in Relapsed\u002FRefractory Diffuse Large B-cell Lymphoma (DLBCL)","CLEAR","Inclusion Criteria:\n\nDisease:\n\n1. Subjects with histologically confirmed relapsed\u002Frefractory DLBCL based on pathology report (WHO 2022 criteria)\n\n   1. DLBCL (de novo or transformed)\n   2. High-grade B-cell lymphoma with MYC and BCL2 rearrangements\n   3. High-grade B-cell lymphoma, not otherwise specified (NOS)\n   4. Follicular lymphoma grade 3B\n\n   Diagnostic biopsy performed at the time of relapse\u002Fprogressive disease no longer than 3 months before study entry must be available, with sufficient material for central review and complimentary scientific analyses. CD20 expression (or a high likelihood of CD20 expression) based on immunohistochemistry should be documented prior enrollment into the study.\n\n   Refractory disease is defined as no remission to the last therapy. Subjects intolerant to previous therapy are excluded. Two groups of patients are eligible:\n   * Progressive disease (PD) or stable disease (SD) as best response to previous therapy.\n   * Complete (CR) or partial response (PR) as the best response after previous therapy, with biopsy-proven relapse occurring \\\u003C 6 months after end of treatment.\n\n   Relapsed disease is defined as subjects achieving complete or partial remission to previous therapy, followed by biopsy-proven relapse ≥6 months after treatment completion. Subjects with refractory and early relapsed (≤12 months) disease after first line anti-CD20-\u002Fanthracycline-containing therapy are eligible. Subjects with late relapsed (\\>12 months) disease after first line anti-CD20-\u002Fanthracycline-containing therapy can be enrolled in the study only if deemed ineligible to high dose chemotherapy (HDCT) followed by autologous stem cell transplantation (ASCT). Subjects relapsed\u002Frefractory to second line CAR-T cell therapy are eligible.\n2. Subject must be 18 years or older.\n3. Subject must be eligible to receive and in need of treatment initiation based on symptoms and\u002For disease burden, as assessed by the investigator.\n4. Eastern Cooperative Oncology Group Performance (ECOG) status 0-2.\n5. Subject must have one or more measurable disease sites defined as follows:\n\n   1. A positron emission tomography\u002Fcomputed tomography (PET\u002FCT) scan demonstrating PET- positive lesion(s) AND\n   2. At least one measurable nodal lesion (long axis \\> 1.5 cm and short axis \\> 1.0 cm) or ≥ one measurable extra-nodal lesion (long axis \\> 1.0 cm) on CT scan or MRI.\n6. Ability to understand and willingness to sign written informed consent. Signed informed consent must be obtained before any study specific procedure.\n\n   Contraception:\n7. Women of childbearing potential and sexually active men must practice a highly effective method of birth control during and after the study, consistent with local regulations regarding the use of birth control methods for subjects participating in clinical trials. Men with female partners who are of childbearing potential must agree to use a condom when sexually active or practice total abstinence from the time of giving informed consent until at least 7 months after the patient receives his last dose of study treatment. Men must agree not to donate sperm from the time of giving informed consent until at least 7 months after the patient receives his last dose of study treatment. For female subjects, they apply for 12 months after the last dose of the study drug. A woman is considered to be of childbearing potential until becoming post-menopausal or permanently sterile. Permanent sterilization methods include hysterectomy, bilateral salpingectomy, and bilateral oophorectomy. Post-menopausal status is defined as no menstrual periods for a continuous 12-month period without an alternative medical cause. A post-menopausal state can be confirmed by a high follicle-stimulating hormone (FSH) level within the postmenopausal range, especially in women not using hormonal contraception or replacement therapy. The investigator or a designated associate will provide guidance to patients on achieving highly effective contraception (with a failure rate of less than 1%), such as intrauterine devices, intrauterine hormone-releasing systems, bilateral tubal occlusion, having a vasectomized partner, or sexual abstinence. Male patients are required to use condoms unless their female partner is permanently sterile.\n8. Women of childbearing potential participating in the study will be required to undergo a pregnancy test using either urine or serum beta-human chorionic gonadotropin (beta-hCG) at the screening visit. A negative result is necessary for inclusion in the study.\n\n   Adequate baseline organ function tests collected no more than 7 days before starting study treatment:\n9. Total bilirubin ≤ 1.5 times the upper limit of normal (ULN), except for patients with Gilbert syndrome, cholestasis due to hepatic hilum adenopathies or liver involvement, or biliary obstruction due to lymphoma, who may have a total bilirubin ≤ 3 times the ULN.\n10. Alanine transaminase (ALT) and aspartate aminotransferase (AST) and gamma-glutamyl transferase (GGT) ≤ 2.5 times the ULN, or ≤ 5 times the ULN for patients with liver involvement by lymphoma.\n11. Glomerular filtration rate (GFR) ≥ 45 mL\u002Fmin\u002F1.73 m² according to the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula. If not initially within target range, this evaluation may be repeated after at least 24 hours, either using the CKD-EPI formula or by 24-hour sampling. If the subsequent result is within the acceptable range, it may be used to fulfill the inclusion criteria.\n12. Prothrombin time\u002Finternational normalized ratio (INR)\u002Factivated partial thromboplastin time (aPTT) ≤ 1.5 times the ULN, unless the patient is receiving anticoagulation (although the INR should not exceed 4.0).\n13. Platelet count ≥ 75,000\u002Fmm³ without transfusion in the prior 7 days.\n14. Hemoglobin ≥ 8 g\u002FdL.\n15. Absolute neutrophil count ≥ 1,000\u002Fmm3 (off growth factors at least 72 hours).\n16. Left ventricular ejection fraction \\> 45%.\n\n    Concomitant Medications:\n17. Subjects should not be taking any active medication known to decrease T-cell numbers or activity, or any other concurrent immunosuppressive medication, except for up to 10 mg of prednisone daily or an equivalent dose, unless it is necessary for disease control during the screening period, premedication and\u002For cytokine release syndrome (CRS)\u002F immune effector cell-associated neurotoxicity syndrome (ICANS) management within the study.\n18. Subjects must not have been treated with any investigational drug within 30 days or 5 half-lives of the drug (whichever is longer) prior to the first dose of the study drug. They should not be currently enrolled in another interventional clinical study or have been previously enrolled in this study, unless the agent being used has been approved under emergency authorization (e.g., anti-severe acute respiratory syndrome coronavirus (SARS-CoV-2) monoclonal antibodies).\n19. Acute toxicity (except alopecia, fatigue) of any prior lymphoma therapy should be resolved to Grade ≤ 1 (with the exception of prior CRS or ICANS that should be fully resolved) at study screening.\n20. The subject should not have received vaccination with live-attenuated vaccines within 28 days prior to screening, and they should not be expected to require any live-attenuated vaccination during their participation in the study, including at least 3 months following the last dose of study treatment. However, vaccination with coronavirus messenger ribonucleic acid (mRNA) and adenovirus-based vaccines, which are not live-attenuated vaccines, is permitted.\n\nExclusion Criteria:\n\nPatients who meet any of the following criteria at the time of screening will be excluded:\n\n1. Any prior lymphoma-directed treatment, except for first-line anti-CD20-\u002Fanthracycline-containing chemoimmunotherapy or second line CAR-T cell therapy. Particularly, patients previously treated with loncastuximab tesirine and any CD3xCD20 bispecific antibody therapy are not eligible.\n2. Patients with late relapse (\\>12 months) after first-line immunochemotherapy considered HDCT\u002FASCT eligible as assessed by the local investigator.\n3. Known central nervous system (CNS) involvement.\n4. Diagnosed or treated for any malignancy other than r\u002Fr DLBCL, HGBL or FL grade 3B within the last 3 years, except for adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease, non-invasive basal cell or squamous cell skin carcinoma, adequately treated carcinoma in situ without evidence of disease, localized prostate cancer, post-radical prostatectomy with non-rising prostate-specific antigen levels \\\u003C 0.1 ng\u002FmL, cervical carcinoma of stage 1B or less, non-invasive, superficial bladder cancer or any curable cancer with a CR of \\> 2 years duration.\n5. Known history of human immunodeficiency virus (HIV) or active hepatitis C virus (HCV) or active hepatitis B virus (HBV) infection or any known active systemic bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds). Patients with serologic markers of HBV immunization due to vaccination (HBsAg negative, Anti-HBc negative, and Anti-HBs positive) will be eligible. Subjects who are positive for hepatitis B core antibody, hepatitis B surface antigen, or hepatitis C antibody must have a negative polymerase chain reaction (PCR) result before enrollment. Those who are PCR positive will be excluded.\n6. Cytomegalovirus (CMV)-PCR positive at baseline.\n7. Any life-threatening illness, medical condition, or organ system dysfunction that, in the investigator's opinion, could compromise the subject's safety or interfere with the feasibility to administer study drugs including active hemophagocytic lymphohistiocytosis\u002Fmacrophage activation syndrome (HLH\u002FMAS), history of cutaneous collagenous vasculopathy and capillary leak syndrome.\n8. Concurrent treatment with another investigational agent or radiation therapy.\n9. Any psychological, cognitive, familial, or social condition that, in the investigator's opinion, compromises the patient's ability to understand the patient information, give informed consent, or comply with the study protocol.\n10. Participation in another clinical trial.\n11. Known history of hypersensitivity and\u002For positive serum human anti-drug antibody (ADA) against any component of the study products or of the concomintant medication or an anti-CD19 antibody.\n12. History of Stevens-Johnson syndrome or toxic epidermal necrolysis.\n13. Clinically significant third space fluid accumulation, such as ascites requiring drainage or pleural effusion that either requires drainage or is associated with shortness of breath.\n14. Pregnancy or breastfeeding.\n15. Use of any other experimental medication within 30 days or 5 half-lives prior to the start of the study drug (Cycle 1 Day 1).\n16. Close affiliation with the investigational site, such as being a close relative of the investigator or dependent person (e.g., employee or student of the investigational site).\n\n    Excluded medical conditions:\n17. Congestive heart failure \\> New York Heart Association (NYHA) class 2.\n18. Unstable angina (angina symptoms at rest) or new-onset angina (begun within the last 3 months).\n19. Uncontrolled atrial or ventricular cardiac arrhythmia.\n20. Left ventricular ejection fraction ≤ 45%.\n21. Electrocardiographic evidence of acute ischemia, coronary angioplasty, or myocardial infarction within 6 months prior to screening.\n22. Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis, or pulmonary embolism within 3 months before the start of study medication.\n23. Congenital long QT syndrome or a QT corrected by Fridericia's formula (QTcF) interval of \\> 480 ms at screening (unless secondary to pacemaker or bundle branch block).\n24. Severe chronic pulmonary disease.\n25. Known clinically significant liver disease, including hepatitis, current alcohol abuse, or cirrhosis.\n26. Autoimmune disease requiring immunosuppressive therapy, except for up to 10 mg prednisone daily (or equivalent).\n27. Seizure disorder requiring therapy within the past 12 months. Subjects with a history of seizure disorder beyond must have a complete CNS workup.\n28. Major surgery within 4 weeks of the first dose of study drugs, except for lymphoma reasons.\n29. Any other co-existing medical or psychological condition that will preclude participation in the study or compromise the ability to give informed consent.",{"count":137,"type":22},120,[26],"This is a phase II study designed to evaluate the toxicity and efficacy of the combination of loncastuximab tesirine and epcoritamab in patients with relapsed\u002Frefractory aggressive B-cell lymphoma. Chimeric antigen receptor (CAR)-T cell naive patients who have failed first-line therapy and patients who have received CAR-T cells as second-line therapy and experienced CAR-T failure will be eligible for inclusion.",[141,142,143],"Aggressive Diffuse Large B-cell Lymphoma","High-grade B-cell Lymphoma (HGBL)","Follicular Lymphoma (FL) Grade 3B",[145,146,147],"Loncastuximab Tesirine","Epcoritamab","Diffuse Large B-cell Lymphoma","2025-09-22",{"date":150,"type":34},"2025-09-29",{"date":152,"type":22},"2025-10-15",{"date":154,"type":22},"2030-01-15",{"name":40,"class":41},{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":162,"eligibilityCriteria":163,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":164,"targetDuration":4,"studyType":23,"phases":166,"briefSummary":168,"conditions":169,"keywords":172,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":184},"100563356","phase-3-reducing-cardiac-surgery-associated-acute-kidney-injury-occurence-by-administering-angiotensin-ii-100563356","NCT06615102","Reducing Cardiac-surgery Associated Acute Kidney Injury Occurence by Administering Angiotensin II","A Prospective Angiotensin II Versus Noradrenaline Trial for Hypotension Management to Reduce Cardiac-surgery Associated Acute Kidney Injury (PAN-AKI)","PAN-AKI","Inclusion Criteria:\n\n1. Cardiac surgery using cardiopulmonary bypass including coronary artery bypass grafting (CABG) surgery, valve surgery, or combined CABG\u002Fvalve surgery\n2. Elevated risk of AKI as predicted by a score ≥ 1.5 on the following scale:\n\n   1. hemoglobin \\\u003C 130g\u002Fl = 2\n   2. creatinine \\> 1.1 mg\u002Fdl = 2\n   3. age \\> 70 years =1.5\n   4. New York Heart Association Classification (NYHA) 4 =1.5\n   5. Body Mass Index (BMI) \\> 30 =1.5\n3. Adult ≥ 18 years\n4. Written informed consent\n\nExclusion Criteria:\n\n1. Major aortic surgery (aortic arch replacement), transplant surgery, pulmonary thrombendarterectomy, ventricular assist device placement\n2. Already receiving inotropic\u002Fvasopressor support before surgery\n3. Dialysis dependent\n4. Pre-existing AKI within the last 30 days\n5. Pre-existing chronic kidney injury with an eGFR\\\u003C20 ml\u002Fmin\u002F1.73m2\n6. Pre-existing significant hypertension (persistent SBP \\> 180mmHg)\n7. Significant pulmonary hypertension (ePSAP \\> 70mmHg, mPAP \\> 40mmHg) with right ventricular systolic dysfunction (graded more severe than mild)\n8. Hypersensitivity to the active substance or to any of the excipients\n9. Pregnancy (a negative pregnancy test for women of childbearing age) or breastfeeding women\n10. Persons with any kind of dependency on the investigator or employed by the sponsor\u002Finvestigator\n11. Participation in another interventional trial within the last three months that investigates kidney function",{"count":165,"type":22},1022,[167],"PHASE3","The study intervention focuses on exploring the use of angiotensin II as a primary vasopressor compared to norepinephrine in cardiac surgery patients to investigate whether angiotensin II can reduce the occurrence of moderate\u002Fsevere acute kidney injury (AKI). Despite its potential, as suggested by trials involving surgical patients, there is currently no human data confirming its effectiveness in preventing moderate\u002Fsevere AKI in this context. The intervention aims to address this gap by evaluating angiotensin II's impact compared to norepinephrine.",[170,171],"Cardiac Surgery","Vasoplegia",[173,174,175],"cardiac surgery","acute kidney injury","Angiotensin II","2025-07-15",{"date":178,"type":34},"2025-07-18",{"date":180,"type":34},"2025-03-31",{"date":182,"type":22},"2027-04",{"name":40,"class":41},4,{"id":186,"slug":187,"hasResults":11,"nctId":188,"briefTitle":189,"officialTitle":190,"acronym":191,"eligibilityCriteria":192,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":193,"targetDuration":4,"studyType":23,"phases":195,"briefSummary":196,"conditions":197,"keywords":199,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":213},"100485195","phase-3-ttf-ngr-randomized-study---sts-100485195","NCT05597917","tTF-NGR Randomized Study - STS","Phase III Study Comparing Trabectedin (T) Versus T Plus tTF-NGR to Entrap T Inside the Tumor in Patients With Metastatic and\u002For Refractory Soft Tissue Sarcoma (STS)","TRABTRAP","Inclusion Criteria:\n\n1. Patients of all genders (female, male, diverse), with no restriction regarding ethnic or religious background age 18 - 75 years.\n2. Patients with advanced or metastatic soft-tissue sarcoma after failure of anthracycline-containing first line therapy (or anthracycline-containing adjuvant therapy within 12 months before entry on study) or with contraindications to these drugs\n3. Patients must have histological evidence of high-grade advanced unresectable or metastatic soft tissue sarcoma (grade 2 - 3) according to the FNCLCC grading system. The following tumor types are included:\n\n   * Dedifferentiated liposarcoma\n   * Myxoid liposarcoma (high grade)\n   * Pleomorphic liposarcoma\n   * Adult fibrosarcoma\n   * Myxofibrosarcoma (high-grade)\n   * Leiomyosarcoma\n   * Rhabdomyosarcoma (alveolar, pleomorphic)\n   * Angiosarcoma\n   * Synovial sarcoma\n   * Undifferentiated sarcoma\n\n   Tumor types not listed above may be included upon communication with Coordinating Investigator.\n\n   The following tumor types will not be included:\n   * Gastrointestinal stromal tumors (GIST)\n   * Epitheloid sarcoma\n   * Alveolar soft part sarcoma\n   * Desmoplastic small round cell tumor\n   * Chondrosarcoma\n   * Osteosarcoma\n   * Ewing sarcoma (including CIC-rearranged sarcoma and Sarcoma with BCOR alterations)\n4. CD13 positivity with a score of ≥ 1 (20) by central pathology (GDI Münster)\n5. Patients must have at least one unidimensionally measurable lesion by computed tomography as defined by RECIST criteria 1.1. Other adequate imaging procedures such as MRI are allowed. This lesion should not have been irradiated during previous treatments\n6. Life expectancy of at least 3 months\n7. Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2\n8. No contraindications for trabectedin (see attachment)\n9. Negative serum pregnancy test for females of childbearing potential\\* within 14 days of starting treatment\n10. Informed consent signed and dated to participate in the study\n11. Willingness and ability to comply with the scheduled visits, treatment plan, laboratory tests and other study procedures\n\n    * Women of childbearing potential (WOCBP) must be using, from the screening to 3 months following the last trabectedin (Arm 1) or the last last study drug (Arm 2) administration, highly effective contraception methods, as defined by the \"Recommendations for contraception and pregnancy testing in clinical trials\" issued by the Head of Medicine Agencies' Clinical Trial Facilitation Group (www.hma.eu\u002Fctfg.html) and which include, for instance, progesteron-only or combined (estrogen- and progesteron-containing) hormonal contraception associated with inhibition of ovulation, intrauterine devices, intrauterine hormone-releasing systems, bilateral tubal occlusion, vasectomized partner or sexual abstinence. Pregnancy test will be repeated monthly. For men contraception methods should be performed for 5 months after the last application of trabectedin (Arm1) or study drug (Arm 2).Women of childbearing potential are defined as females who have experienced menarche, are not postmenopausal (12 months with no menses without an alternative medical cause) and are not permanently sterilized (e.g., tubal occlusion, hysterectomy, bilateral oophorectomy or bilateral salpingectomy)\n\nExclusion Criteria:\n\n1. curative therapy available\n2. clinically significant unrelated illness, which in the judgement of the investigators could compromise the patient's ability to tolerate the IMP or be likely to interfere with the study procedures or results\n3. immobilized tumor patients (wheel chair etc.) with increased risk for DVT\n4. known hypersensitivity reactions to prior application of E. coli-derived material\n5. history of coronary heart disease, stroke, transitent ischemic attacks, pulmonary embolism, or deep vein thrombosis. For reason of mechanism of action of tTF-NGR, exclusion of patients with a history of any of the vascular conditions mentioned is important. Clinical suspicion of coronary heart disease must be further checked e.g. by cardiac MRI or myocardial scintigraphy to exclude coronary heart disease.\n6. known hereditary syndromes with elevated thromboembolic risk (FV Leiden and prothrombin mutations (G20210A), hereditary antithrombin, protein C and S deficiency, and antiphospholipid syndrome) after one or more clinical thromboembolic events\n7. patients with hereditary vascular disorders (such as Klippel-Trenauny-Weber syndrome) with increased thromboembolic risk.\n8. patients with a Khorana score of (Khorana AA, et al. J.Clin. Oncol. 2009, 27, 4839-4847, attached to this protocol) of \\> 3\n9. elevated Troponin T hs (\\> 50 ng\u002FL) or elevated Troponin I hs before entry on study\n10. presence of active central nervous system (CNS) disease and\u002For CNS vascular abnormalities detected by MRI or CT\n11. no adequate bone marrow function, absolute neutrophil count (ANC) \\\u003C 1.0 x 109\u002FL, platelets \\\u003C 50 x 109\u002FL (for trabectedin actually \\\u003C 100 x 109\u002FL - to be decided by the investigator on an individual patient basis) and haemoglobin (Hb) \\\u003C 8.0 g\u002Fdl.\n12. chronically impaired renal function or creatinine ≥ 2.0 x upper limit of normal (ULN).\n13. inadequate liver function (alanine aminotranserase (ALT), aspartate aminotranserase (AST), alkaline phosphatase (ALP) or total bilirubin ≥ 2.5 x ULN) unless due to liver metastasis (decision by the investigator)\n14. fibrinogen \\\u003C 150 mg\u002FdL, and\u002For International Normalized Ratio (INR) \\> 1,5 (global coagulation parameters can be discussed with the Coordinating Investigator prior to entry on study)\n15. female patients with child-bearing who do not agree to exclusion of potential pregnancy by adequate testing within 48 hours prior to entry on study\n16. females of childbearing potential as well as fertile males who do not agree to use a highly effective form of contraception (Pearl Index \\\u003C 1) during the study and for 3 months (females) following the last trabectedin (Arm 1) or last study drug (Arm 2) administration and 5 months (males) following the last dose of trabectedin (Arm 1) or study drug (Arm 2)\n17. women with breast-feeding activity\n18. concomitant use of any other investigational agent (agent for which there is currently no approved indication from regulatory authorities) or any other anti-cancer drug\n19. concomitant enrolment in another clinical trial interfering with the endpoints of this study.\n20. any medical condition which could compromise participation in the study according to the investigator's assessment.\n21. prophylactic or therapeutic anticoagulation within the last 3 days\n22. presence of active and uncontrolled infections or other severe concurrent disease, which, in the opinion of the investigator, would place the patient at undue risk or interfere with the study\n23. concurrent malignancies other than STS, unless the patient has been disease-free for at least 2 years\n24. serious, non-healing wound, ulcer or bone fracture; not completed wound healing from previous wounds and\u002For surgery\n25. no central venous port system in place (the option of other central venous access than a port should be discussed with the Coordinating Investigator).\n\nNOTE: Outliers of laboratory values can be disregarded and set aside as exclusion criteria by a Coordinating Investigator´s decision. The conditions for the use of trabectedin as specified in the Summary of Product Characteristics are to be followed according to institutional guidelines for standard of care.",{"count":194,"type":22},126,[167],"In this phase III open label, controlled clinical trial patients with unresectable or metastatic soft-tissue sarcoma after failure of anthracycline-containing first line therapy or with contraindications to these drugs and CD13 positivity in central histology (grade \\>\u002F= 1+) are treated to evaluate whether tTF-NGR in combination with standard trabectedin chemotherapy prolongs progression-free survival (according to iRECIST), as compared with trabectedin alone. Further objectives are to evaluate the efficacy of tTF-NGR in combination with standard trabectedin chemotherapy with respect to the response rate and overall survival as well as to assess the safety profile of tTF-NGR combined with trabectedin. Before the randomized phase III part of the study, there was a safety run-in part. The final dose of tTF-NGR established as safe in this safety run-in part is 0.5 mg\u002Fm2 per day for 2 consecutive days following each trabectedin infusion and is used for the randomized (parallel 1:1; Arm 1: standard trabectedin, Arm 2: standard trabectedin plus tTF-NGR) phase III part of this trail. . Further dose modification for tTF-NGR is possible.",[198],"Soft Tissue Sarcoma",[200,201,202,203,204],"tTF-NGR","vascular targeting","CD13","aminopeptidase N","Trabectedin","2025-04-01",{"date":207,"type":34},"2025-04-04",{"date":209,"type":34},"2021-10-26",{"date":211,"type":22},"2026-12",{"name":40,"class":41},9,{"id":215,"slug":216,"hasResults":11,"nctId":217,"briefTitle":218,"officialTitle":219,"acronym":220,"eligibilityCriteria":221,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":222,"targetDuration":4,"studyType":224,"phases":4,"briefSummary":225,"conditions":226,"keywords":227,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":232,"startDateStruct":234,"completionDateStruct":236,"leadSponsor":238,"locationsCount":239},"100552431","nephroprotective-measures-in-critically-ill-patients-with-moderatesevere-acute-kidney-injury-100552431","NCT06472999","Nephroprotective Measures in Critically Ill Patients With Moderate\u002FSevere Acute Kidney Injury","Implementation of Nephroprotective Measures in Critically Ill Patients With Moderate\u002FSevere Acute Kidney Injury (AKI) - an Observational Study","KDIGO-Bundle","Inclusion Criteria:\n\n1. Critically ill patients with moderate or severe AKI (KDIGO stage 2 \u002F 3)\n2. Requirement of vasopressors or mechanical ventilation\n3. Age ≥ 18 years\n4. Informed consent\n\nExclusion Criteria:\n\n1. Chronic kidney disease (CKD) with a glomerular filtration rate \\\u003C 20ml\u002Fmin\n2. Chronic dialysis dependency\n3. History of renal transplantation\n4. Permanent ligation of the renal arteries\n5. AKI immediately following nephrectomy\n6. Patients requiring permanent administration of nephrotoxic drugs (e.g. immunosuppressive therapy afer liver transplantation)\n7. Persons with any kind of dependency on the investigator or employed by the sponsor or investigator.",{"count":223,"type":22},257,"OBSERVATIONAL","This study investigates to which extent recommended nephroprotective measures are implemented in critically ill patients with moderate or severe acute kidney injury.",[57],[57,228,229,230],"KDIGO","Nephroprotective","Bundle","2024-12-06",{"date":233,"type":34},"2024-12-12",{"date":235,"type":34},"2024-07-24",{"date":237,"type":22},"2025-09",{"name":40,"class":41},3,{"id":241,"slug":242,"hasResults":11,"nctId":243,"briefTitle":244,"officialTitle":245,"acronym":246,"eligibilityCriteria":247,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":248,"targetDuration":4,"studyType":23,"phases":250,"briefSummary":251,"conditions":252,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":255,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":260,"locationsCount":42},"100503085","remote-ischemic-preconditioning-in-septic-patients-100503085","NCT05830669","Remote Ischemic Preconditioning in Septic Patients","Effect of Remote Ischemic Preconditioning in Septic Patients on Cell Cycle Arrest Biomarkers - the RIPC-ICU Randomized Clinical Trial","RIPC-ICU","Inclusion Criteria:\n\n* Adult patients (age ≥18 years)\n* Critically ill patients with sepsis \\\u003C 12 hours\n* Invasive ventilation for at least 24 hours (propofol-free-sedation) and\u002For vasopressor therapy\n* Unrestricted intensive care for at least 72 hours\n* Written informed consent\n\nExclusion Criteria:\n\n* Pre-existing AKI\n* (Glomerulo-)nephritis, interstitial nephritis, vasculitis\n* Chronic kidney disease with estimated glomerular filtration rate (eGFR) \\\u003C 30 ml\u002Fmin\u002F1.73m²\n* Chronic dialysis dependency\n* Kidney transplant in the last 12 months\n* Oral antidiabetics, sulfonamides or nicorandil\n* Pregnancy or breastfeeding\n* Do-not-reanimate order\n* Participation in another interventional trial involving kidney outcomes within the last 3 months\n* Dependency on the investigator or center",{"count":249,"type":22},64,[54],"Acute kidney injury is a well-recognized complication in critically ill patients. Up to date there is no clinically established method to reduce the incidence or the severity of acute kidney injury.\n\nRemote ischemic preconditioning (RIPC) will be induced by three cycles of upper limb ischemia.\n\nThe aim of the study is to reduce the incidence of AKI by implementing remote ischemic preconditioning (identified by the urinary biomarkers tissue inhibitor of metalloproteinases-2 (TIMP-2) and insulin-like growth factor-binding protein 7(IGFBP7)",[253,57,254],"Critically Ill","Sepsis",{"date":233,"type":34},{"date":257,"type":34},"2023-05-11",{"date":259,"type":22},"2026-01",{"name":40,"class":41},{"id":262,"slug":263,"hasResults":11,"nctId":264,"briefTitle":265,"officialTitle":266,"acronym":267,"eligibilityCriteria":268,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":269,"targetDuration":4,"studyType":224,"phases":4,"briefSummary":271,"conditions":272,"keywords":274,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":278,"startDateStruct":279,"completionDateStruct":281,"leadSponsor":283,"locationsCount":99},"100503328","differential-regulation-of-raas-axis-in-patients-undergoing-cardiac-surgery-100503328","NCT05833828","Differential Regulation of RAAS-axis in Patients Undergoing Cardiac Surgery","Differences in Plasma Concentration of RAAS-axis Hormones in Patients Undergoing Cardiac Surgery With or Without Cardiopulmonary Bypass","RAAS-HLM","Inclusion Criteria:\n\n1. adult patients undergoing on- or off-pump coronary artery bypass graft surgery\n2. written informed consent\n\nExclusion Criteria:\n\n1. emergency surgery in the context of acute coronary syndrome\n2. ACE-inhibitor or Angiotensin 1 (AT1)-receptor-blocker intake that was not paused on the day of surgery\n3. Chronic kidney disease with estimated glomerular filtration rate (eGFR)\\\u003C30ml\u002Fmin\u002F1.73m²\n4. Severe structural lung disease (asbestosis, silicosis, severe sarcoidosis, tuberculosis, severe emphysema, chronic obstructive pulmonary disease (COPD) Gold 3-4, lung fibrosis)\n5. Chronic pulmonary hypertension\n6. Pregnancy or breastfeeding\n7. Persons with any kind of dependency on the investigator or employed by the institution responsible or investigator\n8. Persons held in an institution by legal or official order",{"count":270,"type":22},40,"This study investigates the question of whether there are differences in the plasma concentration of hormones of the RAAS-axis between patients undergoing on-pump cardiac surgery and those receiving off-pump surgery",[171,273],"Vasoplegic Shock",[275,276,277,173],"vasoplegia","vasoplegic shock","cardiopulmonary bypass",{"date":233,"type":34},{"date":280,"type":34},"2023-08-24",{"date":282,"type":22},"2025-08",{"name":40,"class":41},{"id":285,"slug":286,"hasResults":11,"nctId":287,"briefTitle":288,"officialTitle":289,"acronym":290,"eligibilityCriteria":291,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":292,"targetDuration":4,"studyType":23,"phases":294,"briefSummary":295,"conditions":296,"keywords":297,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":299,"lastUpdatePostDateStruct":300,"startDateStruct":302,"completionDateStruct":304,"leadSponsor":306,"locationsCount":99},"100517726","standard-dose-continuous-renal-replacement-therapy-crrt-versus-low-dose-crrt--ketzerei--100517726","NCT06021288","Standard Dose Continuous Renal Replacement Therapy (CRRT) Versus Low-Dose CRRT ( KETZEREI )","A Randomized Controlled Study Investigating Standard Dose Continuous Renal Replacement Therapy (CRRT) Versus Low-Dose CRRT - The \"Ketzerei\" Trial","KETZEREI","Inclusion Criteria:\n\n* Adult patients (age ≥18 years)\n* Critically ill patients with AKI + in need of CRRT\n* Written informed consent\n\nExclusion Criteria:\n\n* Chronic dialysis dependency\n* Chronic kidney disease with estimated glomerular filtration rate (eGFR) \\\u003C30 ml\u002Fmin\u002F1.73m²\n* severe liver cirrhosis (Child-pugh C)\n* severe acidosis (pH \\\u003C 7,20 at study enrolment)\n* severe hyperkalaemia (\\> 6mmol\u002Fl)\n* Pregnancy or breastfeeding\n* persons held in an institution by legal or official order\n* Dependency on the investigator or center",{"count":293,"type":22},165,[54],"Acute kidney injury (AKI) is a well-recognized complication in critically ill patients, which often leads to the necessity of mechanical kidney support (CRRT).\n\nIn current therapeutic regimes, CRRT is used to strictly prevent azotaemia. Thus recent clinical observations, as well as data from animal testing suggest a link between controlled azotaemia and faster renal recovery in AKI patients.\n\nThe aim of the study is to improve renal recovery.",[115,57],[298],"Continuous renal replacement therapy","2024-11-25",{"date":301,"type":34},"2024-11-27",{"date":303,"type":34},"2023-10-02",{"date":305,"type":22},"2025-06-30",{"name":40,"class":41},{"id":308,"slug":309,"hasResults":11,"nctId":310,"briefTitle":311,"officialTitle":312,"acronym":4,"eligibilityCriteria":313,"healthyVolunteers":314,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":315,"targetDuration":4,"studyType":224,"phases":4,"briefSummary":316,"conditions":317,"keywords":319,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":325,"lastUpdatePostDateStruct":326,"startDateStruct":328,"completionDateStruct":329,"leadSponsor":331,"locationsCount":42},"100566264","survey-on-the-evaluation-of-medication-information-leaflets-for-organ-transplant-patients-100566264","NCT06652919","Survey on the Evaluation of Medication Information Leaflets for Organ Transplant Patients","Development and Validation of Materials for the Pharmaceutical Care of Organ Transplant Recipients in Community Pharmacy: Survey on the Evaluation of Medication Information Leaflets for Organ Transplant Patients","Inclusion Criteria:\n\n* Patients who have undergone solid organ transplantation (kidney, liver, heart, lung)\n* Caregivers or family members of organ transplant patients\n* German-speaking individuals\n* adult\n\nExclusion Criteria:\n\n* Individuals who are not able to provide consent\n* Non-German-speaking individuals\n* under 18 years old\n* Patients who have undergone organ transplantation and are no longer taking immunosuppressants",true,{"count":80,"type":22},"The aim of this study is to collect feedback from organ transplant patients or their caregivers\u002Frelatives on the medication information leaflets we've developed, using a questionnaire, and to adjust the content to better meet the specific needs of this unique patient group.",[318],"Organ Transplantation",[320,321,322,323,324],"Organ transplantation","Consumer Information Rating Form","Pharmaceutical Care","Community Pharmacy","Patient Information Leaflets","2024-11-06",{"date":327,"type":34},"2024-11-08",{"date":325,"type":22},{"date":330,"type":22},"2025-03",{"name":40,"class":41},{"id":333,"slug":334,"hasResults":11,"nctId":335,"briefTitle":336,"officialTitle":336,"acronym":4,"eligibilityCriteria":337,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":338,"targetDuration":4,"studyType":224,"phases":4,"briefSummary":340,"conditions":341,"keywords":343,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":348,"lastUpdatePostDateStruct":349,"startDateStruct":351,"completionDateStruct":353,"leadSponsor":355,"locationsCount":42},"100544510","correlation-of-cardiac-output-determined-by-echocardiography-and-indirect-calorimetry-in-critically-ill-patients-in-cardiogenic-shock-on-extracorporeal-circulatory-life-support-100544510","NCT06369818","Correlation of Cardiac Output Determined by Echocardiography and Indirect Calorimetry in Critically Ill Patients in Cardiogenic Shock on Extracorporeal Circulatory Life Support","Inclusion Criteria:\n\n1. Patients that received cardiac surgery\n2. Perioperative requirement of extracorporeal life support (ECLS)\n3. Age ≥ 18 years\n4. Informed consent\n\nExclusion Criteria:\n\n1. Pregnancy or breastfeeding\n2. Relationship or dependency with the study sponsor\n3. Expected survival less than 72 hours after screening",{"count":339,"type":22},50,"This observational study investigates whether the daily measured trend of cardiac output as evaluated by indirect calorimetry correlates with the same evaluated by transthoracic echocardiography.",[342],"Cardiogenic Shock",[344,345,346,347,170],"Indirect calorimetry","cardiac output","Cardiopulmonary bypass (CBP)","Extracorporal circulation (ECLS)","2024-05-17",{"date":350,"type":34},"2024-05-20",{"date":352,"type":34},"2024-01-18",{"date":354,"type":22},"2027-02",{"name":40,"class":41},""]